Regeneron Announces Results of 2026 Annual Meeting of Shareholders

On June 12, 2026, Regeneron Pharmaceuticals, Inc. held its 2026 Annual Meeting of Shareholders. During the meeting, shareholders voted on three key proposals. First, five Class II directors—Joseph L. Goldstein, M.D., Christine A. Poon, David P. Schenkein, M.D., Craig B. Thompson, M.D., and Huda Y. Zoghbi, M.D.—were elected to serve until the 2027 Annual Meeting. Second, the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified with over 102 million votes in favor. Finally, shareholders approved, on an advisory basis, the compensation of the company's named executive officers as disclosed in the April 2026 proxy statement. All proposals passed with the required majority, and the results were formally recorded in this 8-K filing. No other significant corporate developments or clinical updates were disclosed in this report.